This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) ~~Process for the preparation of compounds of the~~ A process for preparing a compound of formula I



I

in which

R is Hal or C≡CH,

R^1 is H, =O, Hal, A, OH, OA, A-COO-, A-CONH-, A-CONA-, N_3, NH_2, NO_2, CN, COOH, COOA, $CONH_2$, CONHA, $CON(A)_2$, O-allyl, O-propargyl, O-benzyl, =N-OH or =N-OA,

R^2 is H, Hal or A,

R^3 is 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2-iminopiperidin-1-yl, 2-iminopyrrolidin-1-yl, 3-iminomorpholin-4-yl, 2-imino-imidazolidin-1-yl, 2-imino-1*H*-pyrazin-1-yl, 2,6-dioxopiperidin-1-yl, 2-oxopiperazin-1-yl, 2,6-dioxopiperazin-1-yl, 2,5-dioxopyrrolidin-1-yl, 2-oxo-1,3-oxazolidin-3-yl, 3-oxo-2*H*-pyridazin-2-yl, 2-caprolactam-1-yl (= 2-oxoazepan-1-yl), 2-azabicyclo[2.2.2]octan-3-on-2-yl, 5,6-dihydro-1*H*-pyrimidin-2-oxo-1-yl, 2-oxo-1,3-oxazinan-3-yl or 4*H*-1,4-oxazin-4-yl, ~~where the radicals may also be~~ which is optionally mono- or disubstituted by A or OA,

A is unbranched, branched or cyclic alkyl having 1-10 carbon atoms, in which~~, in addition,~~ 1-7 H atoms ~~may be~~ are optionally replaced by F,

Hal is F, Cl, Br or I,

~~and~~ or a pharmaceutically ~~usable derivatives, solvates and stereoisomers~~ acceptable salt, mono- or dehydrate, alcoholate or stereoisomer thereof, ~~including mixtures thereof in all ratios, characterised in that~~ comprising

a) reacting a compound of ~~the~~ formula II



II

in which

R^1 is as defined above,

~~is reacted~~ with a compound of ~~the~~ formula III



III

in which

R is as defined above,

to give a compound of ~~the~~ formula IV



IV

in which

R and R^1 are as defined above,

b) a then reacting the compound of ~~the~~ formula IV ~~is then reacted~~ with a compound of ~~the~~ formula V



V

in which R^2 and R^3 are as defined above,

to give a compound of ~~the~~ formula I, and

c) ~~this is, if desired, converted~~ optionally converting the compound of formula I into a pharmaceutically ~~usable derivatives and/or solvates~~ acceptable salt, mono- or dihydrate or alcoholate thereof by converting a base or acid of the compound of formula I into one of its salts, or by bringing together the compound of formula I with water or an alcohol.

2. (Currently Amended) ~~Process~~ A process according to Claim 1, wherein in the compound of formula I ~~for the preparation of compounds of the formula I in which~~

R is F or ~~Cl,~~

~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~.

3. (Currently Amended) ~~Process~~ A process according to Claim 1, wherein in the compound of formula I ~~for the preparation of compounds of the formula I in which~~

R^1 is H, =O, OH, OA, A-COO-, N_3, NH_2, O-allyl or O-propargyl~~,~~

~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~.

4. (Currently Amended) ~~Process~~ A process according to Claim 1, wherein in the compound of formula I ~~for the preparation of compounds of the formula I in which~~

R^1 is H or OH~~,~~

~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~.

5. (Currently Amended) ~~Process~~ A process according to Claim 1, wherein in the compound of formula I ~~for the preparation of compounds of the formula I in which~~

R^3 is 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2-oxopiperazin-1-yl or 3-oxo-2*H*-pyridazin-2-yl~~,~~

~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~.

6. (Currently Amended) ~~Process~~ A process according to Claim 1, wherein in the compound of formula I ~~for the preparation of compounds of the formula I in which~~

A is unbranched or branched alkyl having 1-6 carbon atoms, in which~~, in addition,~~ 1-3 H atoms ~~may be~~ are optionally replaced by F~~,~~

~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~.

7. (Currently Amended) ~~Process~~ A process according to Claim 1, wherein in the compound of formula I ~~for the preparation of compounds of the formula I in which~~

R is Hal or C≡CH,

R^1 is H, OH or OA,

R^2 is H, Hal or A,

R^3 is 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-

yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2-oxopiperazin-1-yl or 3-oxo-2*H*-pyridazin-2-yl,

A is unbranched, branched or cyclic alkyl having 1-10 carbon atoms, in which~~, in addition,~~ 1-7 H atoms ~~may be~~ are optionally replaced by F, and

Hal is F, Cl, Br or ~~I,~~

~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~.

8. (Currently Amended) ~~Process~~ A process according to Claim 1, wherein in the compound of formula I ~~for the preparation of compounds of the formula I in which~~

R is F or Cl,

R^1 is H, =O, OH, OA, A-COO-, N_3, NH_2, O-allyl or O-propargyl,

R^2 is H, F or A,

R^3 is 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2-oxopiperazin-1-yl or 3-oxo-2*H*-pyridazin-2-yl, and

A is unbranched or branched alkyl having 1-6 carbon atoms, in which~~, in addition,~~ 1-3 H atoms ~~may be~~ are optionally replaced by F~~,~~

~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~.

9. (Currently Amended) ~~Process~~ A process according to Claim 1, wherein in the compound of formula I ~~for the preparation of compounds of the formula I in which~~

R is F or Cl,

R^1 is H or OH,

R^2 is H, F or A,

R^3 is 3-oxomorpholin-4-yl, and

A is unbranched or branched alkyl having 1-6 carbon atoms, in which~~, in addition,~~ 1-3 H atoms ~~may be~~ are optionally replaced by F~~,~~

~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~.

10. (Currently Amended) ~~Process~~ A process according to Claim 1, in which the reaction in ~~step~~ a) is carried out in an inert solvent or solvent mixture[[~~,~~]] in the presence of an alkali or alkaline earth metal hydroxide, carbonate or bicarbonate.

11. (Currently Amended) ~~Process~~ A process according to Claim 1, in which the reaction in ~~step~~ a) is carried out in an aqueous $NaHCO_3$ solution.

12. (Currently Amended) ~~Process~~ A process according to Claim 1, in which the reaction in ~~step~~ a) is carried out at a temperature between 60° and 110°C.

13. (Currently Amended) ~~Process~~ A process according to Claim 1, in which the reaction in ~~step~~ b) is carried out in the presence of ethyl 2-ethoxy-1,2-dihydroquinoline-1-carboxylate (EEDQ).

14. (Currently Amended) ~~Process~~ A process according to Claim 1, in which the reaction in ~~step~~ b) is carried out at a temperature between 10° and 70°C.

15. (Currently Amended) ~~Process~~ A process according to Claim 1, in which the reaction in ~~step~~ b) is carried out in tetrahydrofuran.

16. (Currently Amended) ~~Process~~ A process ~~according Claim 1 for the preparation of compounds of the~~ for preparing a compound of formula Ia



Ia

in which

R is F or Cl,

R^1 is H or OH,

R^2 is H, F or A,

R^3 is 3-oxomorpholin-4-yl,

A is unbranched or branched alkyl having 1-6 carbon atoms, in which~~, in addition,~~ 1-3 H atoms ~~may be~~ are optionally replaced by F,

~~and~~ or a pharmaceutically ~~usable derivatives, solvates and stereoisomers~~ acceptable salt, mono- or dehydrate, alcoholate or stereoisomer thereof, ~~including mixtures thereof in all ratios, characterised in that~~ comprising

a) reacting a compound of ~~the~~ formula II



II

in which

R^1 is H or OH,

~~is reacted~~ with a compound of ~~the~~ formula III



III

in which

R is F or Cl,

in an aqueous alkali metal or alkaline earth metal carbonate or bicarbonate solution[[,]] at a temperature between 60° and 110°C,

to give a compound of ~~the~~ formula IV



IV

in which

R is F or Cl,

R^1 is H or OH,

b) ~~a~~ then reacting the compound of ~~the~~ formula IV ~~is then reacted~~ with a compound of ~~the~~ formula V



V

in which

R^2 is H, F or A,

R^3 is 3-oxomorpholin-4-yl, and

A is unbranched or branched alkyl having 1-6 carbon atoms, in which~~, in addition,~~ 1-3 H atoms ~~may be~~ are optionally replaced by F,

in the presence of an auxiliary reagent with formation of a mixed anhydride[[,]] at a temperature between 10° and 70°C,

to give a compound of ~~the~~ formula Ia, and

c) ~~this is, if desired, converted into pharmaceutically usable derivatives and/or solvates~~ optionally converting the compound of formula Ia into a pharmaceutically acceptable salt, mono- or dihydrate or alcoholate thereof by converting a base or acid of the compound of formula Ia into one of its salts, or by bringing together the compound of formula Ia with water or an alcohol.

17. (Currently Amended) ~~Process~~ A process according to Claim 1, wherein the compound of formula I is ~~for the preparation of compounds selected from the group consisting of~~

1-[(4-chlor-phenyl)]-2-{[4-(3-oxo-morpholin-4-yl)-phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-[(4-chlorophenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R)-pyrrolidine-1,2-dicarboxamide,

1-[(4-chlorophenyl)]-2-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R)-pyrrolidine-1,2-dicarboxamide,

1-[(4-chlorophenyl)]-2-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-[(4-chlorophenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2S,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-[(4-chlorophenyl)]-2-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R)-pyrrolidine-1,2-dicarboxamide,

1-[(4-chlorophenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-[(4-chlorophenyl)]-2-{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R)-pyrrolidine-1,2-dicarboxamide,

1-[(4-chlorophenyl)]-2-{[3-trifluoromethyl-4-(3-oxomorpholin-4-yl)-phenyl]}-(2R)-pyrrolidine-1,2-dicarboxamide,

1-[(4-chlorophenyl)]-2-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-[(4-chlorophenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-azidopyrrolidine-1,2-dicarboxamide,

1-[(4-chlorophenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-

aminopyrrolidine-1,2-dicarboxamide,

1-[(4-chlorophenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-[(4-chlorophenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-acetoxypyrrolidine-1,2-dicarboxamide,

1-[(4-chlorophenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R)-4-oxopyrrolidine-1,2-dicarboxamide,

1-[(4-chlorophenyl)]-2-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2S)-pyrrolidine-1,2-dicarboxamide,

1-[(4-chlorophenyl)]-2-{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-[(4-chlorophenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2S,4S)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-[(4-chlorophenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-allyloxypyrrolidine-1,2-dicarboxamide, or

1-[(4-chlorophenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(prop-2-ynyloxy)pyrrolidine-1,2-dicarboxamide,

~~and~~ or a pharmaceutically ~~usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~ acceptable salt, mono- or dehydrate, alcoholate or stereoisomer thereof.

18-20. (Cancelled)

21. (New) A process according to claim 1 for preparing a compound of formula I



I

in which

R is Hal or C≡CH,

R^1 is H, =O, Hal, A, OH, OA, A-COO-, A-CONH-, A-CONA-, N_3, NH_2, NO_2, CN, COOH, COOA, $CONH_2$, CONHA, $CON(A)_2$, O-allyl, O-propargyl, O-benzyl, =N-OH or =N-OA,

R^2 is H, Hal or A,

R^3 is 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2-iminopiperidin-1-yl, 2-iminopyrrolidin-1-yl, 3-iminomorpholin-4-yl, 2-imino-imidazolidin-1-yl, 2-imino-1*H*-pyrazin-1-yl, 2,6-dioxopiperidin-1-yl, 2-oxopiperazin-1-yl, 2,6-dioxopiperazin-1-yl, 2,5-dioxopyrrolidin-1-yl, 2-oxo-1,3-oxazolidin-3-yl, 3-oxo-2*H*-pyridazin-2-yl, 2-caprolactam-1-yl (= 2-oxoazepan-1-yl), 2-azabicyclo[2.2.2]octan-3-on-2-yl, 5,6-dihydro-1*H*-pyrimidin-2-oxo-1-yl, 2-oxo-1,3-oxazinan-3-yl or 4*H*-1,4-oxazin-4-yl, which is optionally mono- or disubstituted by A or OA,

A is unbranched, branched or cyclic alkyl having 1-10 carbon atoms, in which 1-7 H atoms are optionally replaced by F,

Hal is F, Cl, Br or I,

or a pharmaceutically acceptable salt thereof, comprising

a) reacting a compound of formula II



II

in which

R^1 is as defined above,

with a compound of formula III



III

in which

R is as defined above,

to give a compound of formula IV



IV

in which

R and R^1 are as defined above,

b) then reacting the compound of formula IV with a compound of formula V



V

in which R^2 and R^3 are as defined above,

to give a compound of formula I, and

c) optionally concerting the compound of formula I into a pharmaceutically acceptable salt thereof by converting a base or acid of the compound of formula I into one of its salts.

22. (New) A process according to claim 16 for preparing a compound of formula

Ia



Ia

in which

R is F or Cl,

R^1 is H or OH,

R^2 is H, F or A,

R^3 is 3-oxomorpholin-4-yl,

A is unbranched or branched alkyl having 1-6 carbon atoms, in which 1-3 H atoms are optionally replaced by F,

or a pharmaceutically acceptable salt thereof, comprising

a) reacting a compound of formula II



II

in which

R^1 is H or OH,

with a compound of formula III



III

in which

R is F or Cl,

in an aqueous alkali metal or alkaline earth metal carbonate or bicarbonate solution at a temperature between 60° and 110°C,

to give a compound of formula IV



IV

in which

R is F or Cl,

R^1 is H or OH,

b) then reacting the compound of formula IV with a compound of formula V



V

in which

R^2 is H, F or A,

R^3 is 3-oxomorpholin-4-yl, and

A is unbranched or branched alkyl having 1-6 carbon atoms, in which 1-3 H atoms are optionally replaced by F,

in the presence of an auxiliary reagent with formation of a mixed anhydride at a temperature between 10° and 70°C,

to give a compound of formula Ia, and

c) optionally converting the compound of formula Ia into a harmaceutically acceptable salt thereof by converting a base or acid of the compound of

formula Ia into one of its salts.

23. (New) A process according to Claim 21, wherein the compound of formula I is

1-[(4-chlor-phenyl)]-2-{[4-(3-oxo-morpholin-4-yl)-phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-[(4-chlorophenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R)-pyrrolidine-1,2-dicarboxamide,

1-[(4-chlorophenyl)]-2-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R)-pyrrolidine-1,2-dicarboxamide,

1-[(4-chlorophenyl)]-2-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-[(4-chlorophenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2S,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-[(4-chlorophenyl)]-2-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R)-pyrrolidine-1,2-dicarboxamide,

1-[(4-chlorophenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-[(4-chlorophenyl)]-2-{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R)-pyrrolidine-1,2-dicarboxamide,

1-[(4-chlorophenyl)]-2-{[3-trifluoromethyl-4-(3-oxomorpholin-4-yl)-phenyl]}-(2R)-pyrrolidine-1,2-dicarboxamide,

1-[(4-chlorophenyl)]-2-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-[(4-chlorophenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-azidopyrrolidine-1,2-dicarboxamide,

1-[(4-chlorophenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-aminopyrrolidine-1,2-dicarboxamide,

1-[(4-chlorophenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-[(4-chlorophenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-acetoxypyrrolidine-1,2-dicarboxamide,

1-[(4-chlorophenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R)-4-oxopyrrolidine-1,2-dicarboxamide,

1-[(4-chlorophenyl)]-2-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2S)-pyrrolidine-1,2-dicarboxamide,

1-[(4-chlorophenyl)]-2-{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-[(4-chlorophenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2S,4S)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-[(4-chlorophenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-allyloxypyrrolidine-1,2-dicarboxamide, or

1-[(4-chlorophenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(prop-2-ynyloxy)pyrrolidine-1,2-dicarboxamide,

or a pharmaceutically acceptable salt thereof.